Japanese approval and public health insurance coverage for medical-use HAL
First written in FY2016. 5 of 9 entries say "Cited as achieved", first in FY2017-Q1. Latest entry: FY2024-Q3.
No other company in this theme has enough history to compare yet.
- FY2024-Q3RestatedAnnual report
「For spinal cord diseases, approval for additional indications was obtained in October 2022 for two diseases, viral HTLV-1-associated myelopathy (HAM) and hereditary spastic paraplegia, and in October 2023 the Ministry of Health, Labour and Welfare issued a notification on coverage under health insurance.」
For HAM and hereditary spastic paraplegia, we are reaffirming that a notification on health insurance coverage was issued in October 2023 following approval of the additional indications. - FY2024-Q2AdvancedAnnual report
「For spinal cord diseases, approval for additional indications was obtained in October 2022 for two diseases, viral HTLV-1-associated myelopathy (HAM) and hereditary spastic paraplegia, and in October 2023 the Ministry of Health, Labour and Welfare issued a notification on coverage under health insurance.」
For HAM and hereditary spastic paraplegia, following approval of the additional indications, the Ministry of Health, Labour and Welfare issued a notification on health insurance coverage in October 2023, advancing them to the stage of coverage under Japan's public health insurance. - FY2018Cited as achievedAnnual report
「Public health insurance coverage was determined in January 2016, for the first time in the world, and treatment covered by public health insurance for patients with neuromuscular intractable diseases began in September 2016.」
Public health insurance coverage in Japan and the start of treatment in September 2016 are cited as a track record underpinning domestic adoption and expanded coverage. - FY2018-Q2Cited as achievedAnnual report
「Since public health insurance treatment for neuromuscular intractable diseases began in September 2016, the medical-use HAL® lower-limb type (bilateral-leg model) has been increasingly adopted, mainly by designated hospitals in Japan.」
The public health insurance treatment launched in Japan in September 2016 is cited as a track record underpinning expanded adoption at designated hospitals in Japan. - FY2017Cited as achievedAnnual report
「Public health insurance treatment began on 2 September 2016, for the first time in the world.」
The start of treatment covered by Japan's public health insurance continues to be cited as a track record underpinning the medical business. - FY2017-Q3Cited as achievedAnnual report
「For medical-use HAL® (bilateral-leg model), on 25 April 2016 the Ministry of Health, Labour and Welfare published its interpretation of the reimbursement points, including technical fees, for treatment using medical-use HAL® for neuromuscular intractable diseases, making it the world's first robotic treatment to receive a public health insurance reimbursement price. Public health insurance treatment began on 2 September 2016, also for the first time in the world.」
The determination of the public health insurance reimbursement price in Japan and the start of covered treatment are again cited as a track record underpinning the medical business. - FY2017-Q2AdvancedAnnual report
「On 25 April 2016, the Ministry of Health, Labour and Welfare published its interpretation of the reimbursement points, including technical fees, for treatment using medical-use HAL® for neuromuscular intractable diseases, making it the world's first robotic treatment to receive a public health insurance reimbursement price. Public health insurance treatment began on 2 September 2016, also for the first time in the world.」
Following the determination of the public health insurance reimbursement price, treatment covered by public health insurance began on 2 September 2016. - FY2017-Q1Cited as achievedAnnual report
「On 25 April 2016, the Ministry of Health, Labour and Welfare published its interpretation of the reimbursement points, including technical fees, for treatment using medical-use HAL® for neuromuscular intractable diseases, making it the world's first robotic treatment to receive a public health insurance reimbursement price.」
The determination of the public health insurance reimbursement price in Japan is again cited as a track record in the business briefing for the current quarter. - FY2016AchievedAnnual report
「On 25 November 2015, the Ministry of Health, Labour and Welfare granted manufacturing and marketing approval in Japan as a "new medical device" for neuromuscular intractable diseases. On 25 April 2016, the Ministry of Health, Labour and Welfare published its interpretation of the reimbursement points, including technical fees, for treatment using medical-use HAL® (lower-limb type), making it the world's first robotic treatment to receive a public health insurance reimbursement price.」
The Japanese manufacturing and marketing approval and the determination of the public health insurance reimbursement price are described as completed events. The medical fee is stated as a maximum of ¥85,100 to ¥49,600 per treatment.